Discrimination of a single dose of morphine followed by naltrexone: Substitution of other agonists for morphine and other antagonists for naltrexone in a rat model of acute dependence

Journal of Pharmacology and Experimental Therapeutics

Volumn 304, Issue 3, 2003, Pages 1033-1041

  Holtzman, Stephen G ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BUPRENORPHINE; DEXTRORPHAN; DIAMORPHINE; ETORPHINE; FENTANYL; KAPPA OPIATE RECEPTOR AGONIST; LEVORPHANOL; METHADONE; MORPHINE; MU OPIATE RECEPTOR AGONIST; N METHYL N [7 (1 PYRROLIDINYL) 1 OXASPIRO[4.5]DEC 8 YL]BENZENEACETAMIDE; NALTREXONE; OPIATE AGONIST; OPIATE ANTAGONIST; PETHIDINE; SPIRADOLINE;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG DISCRIMINATION; DRUG EFFICACY; DRUG WITHDRAWAL; MALE; MORPHINE ADDICTION; NONHUMAN; OSMOTIC PUMP; PRIORITY JOURNAL; RAT; STEREOCHEMISTRY;

ACUTE DISEASE; ANALGESICS, OPIOID; ANIMALS; DISEASE MODELS, ANIMAL; FENTANYL; MALE; METHADONE; MORPHINE; NALTREXONE; NARCOTIC ANTAGONISTS; RATS; RATS, SPRAGUE-DAWLEY; SUBSTANCE WITHDRAWAL SYNDROME; SUBSTANCE-RELATED DISORDERS;

EID: 0037371165     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: 10.1124/jpet.102.044875     Document Type: Article

References (40)

1. Adams JU and Holtzman SG (1990) Pharmacologic characterization of the sensitization to the rate-decreasing effects of naltrexone induced by acute opioid pretreatment in rats. J Pharmacol Exp Ther 253:483-489.
2. Adams JU and Holtzman SG (1991) Naltrexone-sensitizing effects of centrally administered morphine and opioid peptides. Eur J Pharmacol 193:67-73.
3. Bickel WK, Stitzer ML, Liebson IA, and Bigelow GE (1987) Acute physical dependence in man: effects of naloxone after brief morphine exposure. J Pharmacol Exp Ther 244:126-132.
4. Blasig J, Herz A, Reinhold K, and Zieglgansberger S (1973) Development of physical dependence on morphine in respect to time and dosage and quantification of the precipitated withdrawal syndrome in rats. Psychopharmacologia 33:19-38.
5. Chavkin C, McLaughlin JP, and Celver JP (2001) Regulation of opioid receptor function by chronic agonist exposure: constitutive activity and desensitization. Mol Pharmacol 60:20-25.
6. Easterling KW and Holtzman SG (1997) Intracranial self-stimulation in rats: sensitization to an opioid antagonist following acute or chronic treatment with μ opioid agonists. J Pharmacol Exp Ther 281:188-199.
7. Easterling KW and Holtzman SG (1999) Discriminative stimulus effects of naltrexone after a single dose of morphine in the rat. J Pharmacol Exp Ther288:1269-1277.
8. Eisenberg RM and Sparber SB (1979) Changes in plasma corticosterone levels as a measure of acute dependence upon levorphanol in rats. J Pharmacol Exp Ther 211:364-369.
9. Eissenberg T, Greenwald MK, Johnson RE, Liebson IA, Bigelow GE, and Stitzer ML (1996) Buprenorphine's physical dependence potential: antagonist-precipitated withdrawal in humans. J Pharmacol Exp Ther 276:449-459.
10. 6 glioma cell line expressing the μ opioid receptor. J Pharmacol Exp Ther 278:1121-1127.
11. Finn AK and Whistler JL (2001) Endocytosis of the μ opioid receptor reduces tolerance and a cellular hallmark of opiate withdrawal. Neuron 32:829-839.
12. Gellert VF and Holtzman SG (1978) Development and maintenance of morphine tolerance and dependence in the rat by scheduled access to morphine drinking solutions. J Pharmacol Exp Ther 205:536-546.
13. Gellert VF and Holtzman SG (1979) Discriminative stimulus effects of naltrexone in the morphine-dependent rat. J Pharmacol Exp Ther 211:596-605.
14. Greenwald MK, June HL, Stitzer ML, and Marco AP (1996) Comparative clinical pharmacology of short-acting p opioids in drug abusers. J Pharmacol Exp Ther 277:1228-1236.
15. Holtzman SG (1990) Discriminative stimulus effects of drugs: relationship to potential for abuse, in Testing and Evaluation of Drugs of Abuse (Adler MW and Cowan A eds) pp 195-212, Wiley-Liss, Inc., New York.
16. Holtzman SG (1997) Antagonism of morphine-like discriminative effects by β-funaltrexamine. Pharmacol Biochem Behav 57:771-777.
17. Holtzman SG (2000) Further characterization of the discriminative stimulus effects of spiradoline. Pharmacol Biochem Behav 66:517-522.
18. Lee KO, Akil H, Woods JH, and Traynor JR (1999) Differential binding properties of oripavines at cloned μ- and δ-opioid receptors. Eur J Pharmacol 378:323-330.
19. Maldonado R, Stinus L, Gold LH, and Koob GF (1992) Role of different brain structures in the expression of the physical morphine withdrawal syndrome. J Pharmacol Exp Ther 261:669-677.
20. Meyer DR and Sparber SB (1976) Evidence of possible opiate dependence during the behavioral depressant action of a single dose of morphine. Life Sci 21:1087-1094.
21. Nestler EJ and Aghajanian GK (1997) Molecular and cellular basis of addiction. Science (Wash DC) 278:58-63.
22. Schulteis G, Heyser CJ, and Koob GF (1999) Differential expression of responsedisruptive and somatic indices of opiate withdrawal during the initiation and development of opiate dependence. Behav Pharmacol 10:235-242.
23. Schulteis G, Markou A, Gold LH, Stinus L, and Koob GF (1994) Relative sensitivity to naloxone of multiple indices of opiate withdrawal: a quantitative dose-response analysis. J Pharmacol Exp Ther 271:1391-1398.
24. 35S]GTPγS binding in mMOR-CHO cells and rat thalamus. J Pharmacol Exp Ther 285:496-505.
25. Shannon HE and Holtzman SG (1976) Evaluation of the discriminative effects of morphine in the rat. J Pharmacol Exp Ther 198:54-65.
26. Shannon HE and Holtzman SG (1977) Further evaluation of the discriminative effects of morphine in the rat. J Pharmacol Exp Ther 201:55-66.
27. Sharma SK, Klee WA, and Nirenberg M (1975) Dual regulation of adenylate cyclase accounts for narcotic dependence and tolerance. Proc Natl Acad Sci USA 72:3092-3096.
28. Shippenberg TS, Funada M, and Schutz CG (2000) Dynorphin A (2-17) attenuates the unconditioned but not the conditioned effects of opiate withdrawal in the rat. Psychopharmacology 151:351-358.
29. Smith MA and Picker MJ (1995) Examination of the κ agonist and antagonist properties of opioids in the rat drug discrimination procedure: influence of training dose and intrinsic efficacy. Behav Pharmacol 6:703-717.
30. Sternini C, Spann M, Anton B, Keith DE Jr, Bunnett NW, Von Zastrow M, Evans C, and Brecha NC (1996) Agonist-selective endocytosis of μ opioid receptor by neurons in vivo. Proc Natl Acad Sci USA 93:9241-9246.
31. 2 analysis for naltrexone antagonism of discriminative stimulus and analgesic effects of opiate agonists in rats. J Pharmacol Exp Ther 271:959-968.
32. Wang DX, Raehal KM, Bilsky EJ, and Sadée W (2001) Inverse agonists and neutral antagonists at μ opioid receptor (MOR): possible role of basal receptor signaling in narcotic dependence. J Neurochem 77:1590-1600.
33. Wang Z, Bilsky EJ, Porreca F, and Sadee W (1994) Constitutive μ opioid receptor activation as a regulatory mechanism underlying narcotic tolerance and dependence. Life Sci 54:L339-L350.
34. Way EL (1967) Brain uptake of morphine: pharmacologic implications. Fed Proc 26:1115-1118.
35. Way EL, Loh HH, and Shen FH (1969) Simultaneous quantitative assessment of morphine tolerance and physical dependence. J Pharmacol Exp Ther 167:1-8.
36. Whistler JL, Chuang HH, Chu P, Jan LY, and Von Zastrow M (1999) Functional dissociation of μ opioid receptor signaling and endocytosis: implications for the biology of opiate tolerance and addiction. Neuron 23:737-746.
37. White DA and Holtzman SG (2001) Acute opioid pretreatment potentiates naltrexone-induced drinking suppression in water-deprived rats. J Pharmacol Exp Ther 298:156-164.
38. Wright C, Bigelow GE, Stitzer ML, and Liebson IA (1991) Acute physical dependence in humans: repeated naloxone-precipitated withdrawal after a single dose of methadone. Drug Alcohol Depend 27:139-148.
39. Young AM (1986) Effects of acute morphine pretreatment on the rate-decreasing and antagonist activity of naloxone. Psychopharmacology 88:201-208.
40. Young AM, Kapitsopoulos G, and Makhay MM (1991) Tolerance to morphine-like stimulus effects of μ opioid agonists. J Pharmacol Exp Ther 257:795-805.